Charles River Laboratories Announces Second-Quarter 2016 Results from Continuing Operations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Charles River Labs (CRL) PT Raised to $100 at Jefferies
August 4, 2016 10:50 AM EDTJefferies analyst raised his price target on Buy-rated Charles River Labs (NYSE: CRL) to $100.00 (from $94.00) following recent earnings.
commented, "CRL displayed continued strength across all segments. Integration of WIL is underway and should lead to margin leverage from the $17-20M cost synergies. CRL is the pre-clinical CRO "category killer" and continues to drive share gains and revenue growth through comprehensive offerings and a focus on high quality science with benefits to utilization, price, and margin."
The analyst had 4 Key Insights:
1) DSA Outperforms in 1st Quarter with WIL. DSA revenue grew... More
Charles River Labs (CRL) PT, Estimates Raised at Evercore ISI
August 3, 2016 11:08 AM EDTEvercore ISI analyst Ross Muken raised estimates and his price target on Charles River Labs (NYSE: CRL) to $91.50 (from $83.50) but maintained a Hold rating.
Muken commented, "Charles Rivers epic nine quarter run continued (core growth in HSD) as biopharma end market strength remains the main story. Strong demand across the... More
Charles River Laboratories (CRL) Tops Q2 EPS by 10c; Bumps Outlook Higher
August 3, 2016 7:05 AM EDTCharles River Laboratories (NYSE: CRL) reported Q2 EPS of $1.20, $0.10 better than the analyst estimate of $1.10. Revenue for the quarter came in at $434.1 million versus the consensus estimate of $425.08 million.
James C. Foster, Chairman, President and Chief Executive Officer, said, I am very pleased to... More
